coagulopathy

(redirected from Blood coagulation disorders)
Also found in: Dictionary, Wikipedia.

coagulopathy

 [ko-ag″u-lop´ah-the]
any disorder of blood coagulation.
consumption coagulopathy disseminated intravascular coagulation.

co·ag·u·lop·a·thy

(kō'ag-yū-lop'ă-thē),
A disease affecting the coagulability of the blood.

coagulopathy

/co·ag·u·lop·a·thy/ (ko-ag″u-lop´ah-the) any disorder of blood coagulation.
consumption coagulopathy  disseminated intravascular coagulation.

coagulopathy

[kō·ag′yəlop′əthē]
a pathologicalondition that reduces the ability of the blood to coagulate, resulting in uncontrolled bleeding.

coagulopathy

Hematology A clotting defect in which bleeding does not stop in the usual time period Etiology Hemophilia, drug-induced defects–eg, aspirin, thrombocytopenia, liver disease, Von Willebrand's disease. See Consumption coagulopathy, DIC, Leukemic coagulopathy.

co·ag·u·lop·a·thy

(kō-ag'yū-lop'ă-thē)
A disease affecting the coagulability of the blood.

Coagulopathy

A disorder in which blood is either too slow or too quick to coagulate (clot).
Mentioned in: Cerebral Palsy

coagulopathy

any disorder of blood coagulation. See also hemophilia.

consumption coagulopathy
a bleeding tendency due to a reduction in clotting factors caused by their utilization. See also disseminated intravascular coagulation.
disseminated intravascular coagulopathy (DIC)
see disseminated intravascular coagulation.
hepatic coagulopathy
impaired synthesis of most clotting factors, including factors I, II, V, VII, IX and X, as well as other substances involved in the fibrinolytic system, in severe liver disease can cause significant abnormalities in coagulation.
References in periodicals archive ?
Life Science Analytics', Haemophilia and Blood Coagulation Disorders Therapy Area Pipeline Report contains detailed information on the haemophilia and blood coagulation disorders drug pipeline.
Top 20 companies in late stage Hemophilia or Blood Coagulation Disorders Projects
Top 20 companies in early stage Hemophilia or Blood Coagulation Disorders Projects
The terms of the license agreement allow Diazyme to develop and market worldwide two PNA-based specific SNP kits to test for human blood coagulation disorders.
Factor V Leiden is the most common hereditary blood coagulation disorder in the United States, present in 5% of the white Caucasian population and present in 1.
Biopool International manufactures a full range of test kits to assess and diagnose blood coagulation disorders, thrombotic risk factors, fibrinolysis, platelet function and the vascular system, specialty chemistry controls used to monitor and measure the presence of drugs of abuse, and blood group serology products used to screen for antibodies and group and type whole blood.
Risk factors include: high blood pressure, alcohol and drug abuse, blood coagulation disorders and some anti-coagulant medications.
Compounds currently under development at Molecumetics are designed to treat heart disease, blood coagulation disorders, inflammatory diseases such as asthma and arthritis, and cancer.
Molecumetics currently has partnerships with Asahi Chemical Industries and Teijin Limited aimed at identifying compounds to treat heart disease and blood coagulation disorders.
In return, Bayer will receive a worldwide exclusive license to Immune Response's proprietary gene delivery technology for the delivery of the Factor VIII gene and the option to enter into negotiations with Immune Response to use this technology to treat other blood coagulation disorders.
With the completion of this collaboration agreement, TKT has enhanced its position as a strong player in the development and commercialization of gene therapy products for blood coagulation disorders.